XML 36 R26.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Segment Data (Tables) | 9 Months Ended
--- | ---
Jun. 30, 2024
Segment Reporting [Abstract] |
Revenue from External Customers by Geographic Area | Revenues by segment, organizational unit and geographical areas for the three and nine-month periods are detailed below. The Company has no material intersegment revenues.
| Three Months Ended June 30,
(Millions of dollars) | 2024 |  | 2023
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 670 |  |  | $ | 453 |  |  | $ | 1,123 |  |  | $ | 628 |  |  | $ | 459 |  |  | $ | 1,086 |
Medication Management Solutions | 680 |  |  | 160 |  |  | 840 |  |  | 587 |  |  | 167 |  |  | 754 |
Pharmaceutical Systems | 158 |  |  | 437 |  |  | 594 |  |  | 186 |  |  | 408 |  |  | 594 |
Total segment revenues | $ | 1,508 |  |  | $ | 1,050 |  |  | $ | 2,558 |  |  | $ | 1,400 |  |  | $ | 1,033 |  |  | $ | 2,434 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 405 |  |  | $ | 491 |  |  | $ | 896 |  |  | $ | 398 |  |  | $ | 460 |  |  | $ | 858 |
Biosciences | 141 |  |  | 222 |  |  | 363 |  |  | 148 |  |  | 220 |  |  | 368 |
Total segment revenues | $ | 546 |  |  | $ | 714 |  |  | $ | 1,260 |  |  | $ | 546 |  |  | $ | 680 |  |  | $ | 1,226 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 283 |  |  | $ | 93 |  |  | $ | 376 |  |  | $ | 298 |  |  | $ | 90 |  |  | $ | 388 |
Peripheral Intervention | 263 |  |  | 225 |  |  | 488 |  |  | 256 |  |  | 225 |  |  | 481 |
Urology and Critical Care | 297 |  |  | 78 |  |  | 375 |  |  | 272 |  |  | 77 |  |  | 349 |
Total segment revenues | $ | 844 |  |  | $ | 396 |  |  | $ | 1,240 |  |  | $ | 826 |  |  | $ | 392 |  |  | $ | 1,218 |
Other (a) | $ | (6) |  |  | $ | (62) |  |  | $ | (67) |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total Company revenues | $ | 2,891 |  |  | $ | 2,098 |  |  | $ | 4,990 |  |  | $ | 2,772 |  |  | $ | 2,106 |  |  | $ | 4,878 |
(a) Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5.
| Nine Months Ended June 30,
(Millions of dollars) | 2024 |  | 2023
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 1,971 |  |  | $ | 1,310 |  |  | $ | 3,282 |  |  | $ | 1,863 |  |  | $ | 1,332 |  |  | $ | 3,195 |
Medication Management Solutions | 1,883 |  |  | 475 |  |  | 2,359 |  |  | 1,701 |  |  | 483 |  |  | 2,184 |
Pharmaceutical Systems | 442 |  |  | 1,154 |  |  | 1,596 |  |  | 478 |  |  | 1,092 |  |  | 1,570 |
Total segment revenues | $ | 4,297 |  |  | $ | 2,940 |  |  | $ | 7,237 |  |  | $ | 4,042 |  |  | $ | 2,907 |  |  | $ | 6,949 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 1,286 |  |  | $ | 1,451 |  |  | $ | 2,737 |  |  | $ | 1,327 |  |  | $ | 1,371 |  |  | $ | 2,699 |
Biosciences | 426 |  |  | 689 |  |  | 1,115 |  |  | 444 |  |  | 660 |  |  | 1,104 |
Total segment revenues | $ | 1,712 |  |  | $ | 2,139 |  |  | $ | 3,852 |  |  | $ | 1,772 |  |  | $ | 2,031 |  |  | $ | 3,803 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 851 |  |  | $ | 273 |  |  | $ | 1,124 |  |  | $ | 880 |  |  | $ | 252 |  |  | $ | 1,131 |
Peripheral Intervention | 762 |  |  | 669 |  |  | 1,431 |  |  | 748 |  |  | 635 |  |  | 1,383 |
Urology and Critical Care | 930 |  |  | 234 |  |  | 1,165 |  |  | 794 |  |  | 225 |  |  | 1,019 |
Total segment revenues | $ | 2,543 |  |  | $ | 1,177 |  |  | $ | 3,720 |  |  | $ | 2,421 |  |  | $ | 1,112 |  |  | $ | 3,533 |
Other (a) | $ | (6) |  |  | $ | (62) |  |  | $ | (67) |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total Company revenues | $ | 8,546 |  |  | $ | 6,195 |  |  | $ | 14,741 |  |  | $ | 8,235 |  |  | $ | 6,050 |  |  | $ | 14,285 |
(a) Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5.
Financial Information for Company's Segments | Segment income for the three and nine-month periods was as follows:
| Three Months Ended June 30, |  | Nine Months Ended June 30,
(Millions of dollars) | 2024 |  | 2023 |  | 2024 |  | 2023
Income Before Income Taxes |  |  |  |  |  |  |
Medical (a) | $ | 753 |  |  | $ | 588 |  |  | $ | 1,950 |  |  | $ | 1,783 |
Life Sciences | 387 |  |  | 343 |  |  | 1,174 |  |  | 1,171 |
Interventional | 365 |  |  | 323 |  |  | 1,044 |  |  | 922 |
Total Segment Operating Income | 1,505 |  |  | 1,254 |  |  | 4,168 |  |  | 3,875 |
Integration, restructuring and transaction expense | (112) |  |  | (70) |  |  | (288) |  |  | (175) |
Net interest expense | (89) |  |  | (95) |  |  | (265) |  |  | (299) |
Other unallocated items (b) | (804) |  |  | (618) |  |  | (2,124) |  |  | (1,920) |
Total Income Before Income Taxes | $ | 500 |  |  | $ | 471 |  |  | $ | 1,491 |  |  | $ | 1,481 |
(a)The amounts for the three and nine months ended June 30, 2023 included charges recorded to Cost of products sold of $90 million to adjust estimated future product remediation costs. (b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration